antibody levels – Page 4 – Communicable Diseases Research

Seroprevalence of Anti-S1-RBD Antibodies in Pre-pandemic and Pandemic Subjects From Hail Region, KSA

우박 지역, KSA의 전염병 전 및 전염병 대상체에서 항-S1-RBD 항체의 혈청유병률

Article

Published on 2022-06-092022-09-11
Journal: Frontiers in Public Health [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals

SARS-CoV-2 회복기 개인의 증상에 따른 차등 항체 생산

Article

Published on 2022-06-092022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법,

[키워드] 95% CI absence adjusted odds ratio age analyzed antibody antibody levels antibody production Antibody Response Antibody responses association associations Bio-rad characterized convalescent individual convalescent plasma correlated COVID-19 symptom COVID-19 symptoms detectable ELISA exhibiting generate identify IgA IgG IgM individual infected with SARS-CoV-2 information lack Logistic regression nucleocapsid plasma Rapid test rapid test) RBD Receptor binding domain respiratory respiratory symptom robust S1 subunit SARS-CoV-2 SARS-CoV-2 infected individual SARS-CoV-2 infected individuals SARS-COV-2 infection seropositive Severity of infection Sex significantly sore throat Support Symptom tested the antibody response was used without symptom
[DOI] 10.1371/journal.pone.0264298 PMC 바로가기 [Article Type] Article

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구

Clinical Trial

Published on 2022-06-092022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year
[DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial

mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273

청소년의 mRNA 또는 ChAd0x1 COVID-19 예방 접종은 mRNA-1273에 이어 오미크론을 계속 인식하여 강력한 항체 및 세포 반응을 유도합니다

Article

Published on 2022-06-022022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] Adolescent antibody antibody level antibody levels Antibody Response BNT162b2 CD4+ T-cell Cell cellular response Cellular responses ChAdOx1 comprehensive analysis COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines cytokine develop dominant Donor doses dual elicit Evidence generate health condition High-risk patients IL-10 immune response immune responses immunogenic Infection measure memory Mild mRNA mRNA vaccination mRNA vaccine mRNA-1273 natural infection neuro-disabilities neutralisation titre Neutralisation titres omicron Omicron variant paediatric physical populations reactivity Recognition remained response risk robust severe disease significantly increased single vaccination Strong T-cell T-cell Response T-cell responses T-cells These data vaccination Vaccine vaccine dose variant
[DOI] 10.3389/fimmu.2022.882515 PMC 바로가기 [Article Type] Article

Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia

러시아 상트페테르부르크 인구에서 SARS-CoV-2 항체의 유병률과 역학

Article

Published on 2022-06-012022-09-11
Journal: Journal of Epidemiology and Global Health [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Antibody detection antibody levels Chain Reaction connection coronavirus coronavirus disease COVID-19 database decrease Dynamics effective Epidemiological study Follow-up IgA IgG IgM Immunity Laboratory lockdown measure Measures Patient PCR PCR test polymerase chain polymerase chain reaction Population Post-infection Prevalence proportion Quantitative quarantine remained respiratory Retrospective analysis Russia Saint Petersburg SARS-CoV-2 SARS-CoV-2 detection seropositive seropositive status Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus significant difference significant differences spread of COVID-19 state test results university was performed
[DOI] 10.1007/s44197-022-00041-9 PMC 바로가기 [Article Type] Article

Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants

Delta 및 Omicron 변이체에 대한 COVID-19 백신 반응 및 3차 추가접종량 유도 중화항체의 비교 분석

Article

Published on 2022-05-052022-09-11
Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment

투석에서의 코로나19: 임상적 영향, 면역 반응, 예방 및 치료

Review

Published on 2022-05-012022-09-11
Journal: Kidney international [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법,

[키워드] absence adenoviral vector vaccine adverse effect antibody antibody levels BNT162b2 BNT162b2 vaccine booster dose candidate Candidates Care clinical impact Course COVID-19 COVID-19 pandemic develop dialysis disease severity dose Evidence Hemodialysis Hospitalization humoral immune response immune Immune escape immune response immune responses Immunity immunogenicity increase increased risk Infection initial long-lasting monoclonal antibody Mortality mRNA mRNA vaccines mRNA-1273 mRNA-1273 vaccine neutralizing monoclonal antibodies Patient Preliminary data prolonged viral shedding Prophylaxis PROTECT Psychological distress Reinfection responses reveal robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 variant SARS-CoV-2 variants severe disease significantly survivor Therapeutic strategies therapeutic strategy Treatment vaccination vaccine response Viral viral shedding virtue
[DOI] 10.1016/j.kint.2022.01.022 PMC 바로가기 [Article Type] Review

Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination

SARS-CoV-2 감염 300일 후 항체 반응 중화 및 백신 접종 후 고항체 역가 유도

Article

Published on 2022-05-012022-09-11
Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] absence Anti-RBD antibodies Anti-RBD antibody antibody antibody level antibody levels Antibody Response Antibody titer Antibody titers Antibody-mediated immunity benefit COVID-19 COVID-19 patient COVID-19 patients COVID-19 vaccination declined detect detectable disease health institution Immunity individual individuals Infection Local Neutralizing antibodies neutralizing antibody Neutralizing antibody titer outbreak PROTECT RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 ⋅ COVID-19 ⋅ Vaccines ⋅ antibody titers ⋅ waning immunity. SARS-COV-2 infection SARS-CoV-2 spike spike These data vaccinated individual vaccination vaccine dose virus waning immunity
[DOI] 10.1002/eji.202149758 PMC 바로가기 [Article Type] Article

An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey

터키 의료 종사자의 코로나백 2차 접종 후 항체 반응 및 BNT162b2 또는 코로나백 추가 접종 후 체액성 반응 분석

Article

Published on 2022-05-012022-09-11
Journal: Journal of medical virology [Category] Fulltext, MERS, 변종, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age Analysis Anti-RBD IgG anti-receptor-binding domain antibody antibody levels Antibody Response asked blood draw BNT162b2 booster booster dose booster doses chronic disease circulating variants Complete CoronaVac coronavirus dose evaluated Follow-up groups healthcare worker Healthcare workers Heterologous heterologous vaccination homologous or heterologous humoral Humoral response IgG Immunoglobulin Immunoglobulin G Inactivated vaccine independent predictor independent predictors levels of antibody Limited Messenger RNA Odds ratio participant Participants prospective cohort study Quantitative questionnaire RBD reduction respiratory risk SARS-CoV-2 second dose Seropositivity severe acute respiratory syndrome Coronavirus single booster dose the median Turkey university hospital vaccination Vaccine waning immunity were infected were measured
[DOI] 10.1002/jmv.27620 PMC 바로가기 [Article Type] Article

A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days

비활성화 백신의 세 번째 접종은 항 SARS-CoV-2 항체의 수준과 붕괴 시간을 극적으로 증가시켰지만 다시 실망스럽게 감소했습니다: 368일 동안 18개의 연속 시점에서 전향적, 종적, 코호트 연구

Article

Published on 2022-04-292022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] 95% CI activate administration anti-RBD anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody Anti-spike anti-Spike IgG antibody antibody levels booster dose carried conversion rate CoronaVac COVID-19 Day decay dose Efficacy evaluate FIVE fold half-life half-live half-lives IgA IgA level IgG IgM immune immune characteristics immune protection Immunity inactivated Increased Level longitudinal management much lower neutralizing antibody over Point positive positive conversion Predictive predictive values Prospective prospective cohort study regimen regimens remained response revaccination SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants second dose subset the SARS-CoV-2 time vaccination Vaccine volunteers
[DOI] 10.3389/fimmu.2022.876037 PMC 바로가기 [Article Type] Article